3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
30
Terminated
8
Withdrawn
4
Unknown
4
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
31
Squamous Cell Carcinoma of Head and Neck
21
Carcinoma, Non-Small-Cell Lung
20
Neoplasms
18
Breast Neoplasms
18
Glioblastoma
17
Esophageal Squamous Cell Carcinoma
16
Rectal Neoplasms
15
Lung Neoplasms
15
Esophageal Neoplasms
15
Head and Neck Neoplasms
12
Uterine Cervical Neoplasms
11
Neoplasm Metastasis
10
Glioma
10
Nasopharyngeal Carcinoma
8
Stomach Neoplasms
7
Radiation Injuries
7
Oropharyngeal Neoplasms
7
Brain Neoplasms
7
Hyperthermia
6
Carcinoma, Hepatocellular
6
Astrocytoma
6
Urinary Bladder Neoplasms
5
Small Cell Lung Carcinoma
5
Sarcoma
5
Oligodendroglioma
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Interventions
venetoclax
124
Azacitidine
96
Cytarabine
71
fludarabine
44
Specimen Handling
38
Cyclophosphamide
38
Daunorubicin
27
Decitabine
26
Biopsy
25
Idarubicin
24
Granulocyte Colony-Stimulating Factor
21
gilteritinib
18
Injections
18
fludarabine phosphate
17
Whole-Body Irradiation
17
Melphalan
16
Busulfan
16
Stem Cell Transplantation
15
Mycophenolic Acid
15
ivosidenib
13
Cladribine
13
decitabine and cedazuridine drug combination
12
Gemtuzumab
12
Tacrolimus
11
CPX-351
11
X-Rays
10
Filgrastim
10
revumenib
9
enasidenib
9
Cyclosporine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, Myeloid, Acute
×
Radiotherapy
×
Clear all
NCT04678401
2025-10-20
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Phase 1
Recruiting
30 enrolled